Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Alumis (NASDAQ:ALMS) stock surges 14% after the company reached a licensing deal with Kaken (KKPCF) for its skin disorder ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...